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Purpose: Matrix metalloproteinases are enzymes capable of breaking down all of the components of the extracellular
matrix and have been implicated in the development of aneurysm formation. Because matrix metalloproteinase–9
(MMP-9) levels are elevated in aortic aneurysmal tissue and in that patient plasma, we hypothesized that plasma MMP-9
levels should decrease significantly after conventional and endovascular infrarenal abdominal aortic aneurysm (AAA)
repair but that plasma MMP-9 levels would remain elevated in patients with endoleaks.
Methods: A sandwich enzyme-linked immunosorbent assay was used to measure plasma levels of MMP-9 in patients with
AAA who underwent conventional (n 26; mean age, 71.5 years) and endovascular (n 25; mean age, 76.4 years) AAA
repair. Levels were drawn before surgery and at 1 month and 3 months after surgery. Eight patients for endovascular
repair had endoleaks identified on postoperative computed axial tomographic scans.
Results: No correlation existed between preoperative plasma MMP-9 levels when compared with age, gender, or aneurysm
diameter. No significant difference in preoperative plasma MMP-9 levels or AAA diameter was identified between patients
with conventional repair compared with endovascular repair. Of the 51 patients, 33 had follow-up samples available for
analysis. A significant increase in mean plasma MMP-9 levels was noted 1 month (149.5  40.1 ng/mL) after
conventional AAA repair compared with preoperative levels (83.9  26.1 ng/mL; P < .05) and remained elevated 3
months after surgery (129.8 56.6 ng/mL). In those patients who underwent endovascular aneurysm exclusion without
endoleak, a significant decrease in mean plasma MMP-9 levels was noted at 3 months (27.4  5.2 ng/mL) when
compared with preoperative values (60.8  8.8 ng/mL; P < .01). In contrast, patients with endoleak after endovascular
exclusion did not have a significant decrease in plasma MMP-9 levels at 3 months.
Conclusion: Plasma MMP-9 levels remain elevated for as much as 3 months after conventional AAA repair, whereas
successful endovascular exclusion of an AAA results in decreased plasma MMP-9 levels by 3 months. MMP-9 may have
clinical value as an enzymatic marker for endoleak after endovascular AAA exclusion. (J Vasc Surg 2002;35:916-22.)
In the past 50 years, extraordinary strides have been
made in understanding the pathogenesis of aneurysmal
disease and in its surgical treatment with the advent of
endovascular stent grafting.1 As the understanding of aortic
aneurysmal disease becomes more sophisticated, vascular
surgeons are using new techniques to reduce the morbidity
and mortality rates associated with aneurysm rupture and to
avoid complications associated with the procedure.
Collagen and elastin play important roles in the struc-
ture and function of the aorta.2 Matrix metalloproteinases
are soluble, zinc-dependent enzymes produced by macro-
phages and smooth muscle cells that are capable of
breaking down components of the extracellular matrix
and have been implicated by many investigators in the
development of aneurysm formation.3-6 Matrix metallo-
proteinase-9 (MMP-9) has elastolytic activity that may act
in concert with proteases and other metalloproteinases to
affect structural arterial changes in aneurysmal disease.7
Elevated MMP-9 levels in aortic aneurysmal tissue, and in
that patient plasma, have been shown.8 This increased
enzyme level has been implicated in the progression of
aneurysmal disease.
Since its introduction in 1991, endovascular abdominal
aortic aneurysm (AAA) repair has been shown to be a viable
alternative to open repair in short to medium term fol-
low-up periods. Compared with conventional repair, endo-
vascular repair leaves the aneurysm sac in situ and undis-
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turbed. After exclusion, thrombosis and regression of the
aneurysm sac are expected. However, in a subset of pa-
tients, an endoleak persists or develops that continually
exposes the aneurysm sac to arterial pressure and blood
flow. Stent migration or graft component separation can
lead to type I endoleak. Although the exact association
between a type II endoleak and the risk for aneurysm
rupture is not known, because the sac remains under pres-
sure, the potential for growth and rupture still exists. Type
II endoleaks commonly occur via patent lumbar or inferior
mesenteric arteries. Indeed, at least 25 cases of aneurysm
rupture after endovascular repair have been reported to the
Food and Drug Administration.9 Detection and treatment
of endoleak is, therefore, crucial to successful endovascular
aneurysm repair. Thus, a biologically relevant marker of
aneurysm disease and its trend after aneurysm repair would
be valuable in identifying these patients at risk of aneurysm
rupture. Diagnosis has depended on computed tomo-
graphic (CT) scanning to visualize flow in the aneurysm
sac. However, the sensitivity of this imaging method is not
100%.10,11 Excluded aneurysms have continued to enlarge
without demonstrable flow in the aneurysm sac and conse-
quently are still at risk for rupture.11
This study suggests that plasma levels of MMP-9 can be
used as a marker for persistent endoleak in those patients
who undergo endovascular repair of an AAA. The specific
aims of the study were to determine whether plasma
MMP-9 levels drop significantly after conventional and
endovascular AAA repair and to determine whether pa-
tients with persistent endoleaks after endovascular repair
have persistently elevated plasma MMP-9 levels. To date,
we are unaware of any study that has compared the re-
sponse of plasma MMP-9 with conventional AAA repair
and endovascular exclusion or has investigated its implica-
tions for the diagnosis of endoleak.
METHODS
All patients who underwent elective infrarenal AAA
repair between September 2000 and April 2001 were eligi-
ble for study inclusion. Informed consent was obtained in
accordance with the Institutional Review Board of the
Medical College of Wisconsin and the Veterans Adminis-
trations Medical Center in Milwaukee. Fifty-one patients
were enrolled in the study. Excluded were those patients
who were unwilling to participate and those with aneurysm
rupture.
Conventional aneurysm repair implanted Dacron aortic
interposition or bifurcated grafts, handsewn with prolene
suture. The residual aneurysm sac was closed around the
aortic graft. Endovascular aneurysm exclusion was accom-
plished with the two commercially available (AneuRx,
Medtronics, Santa Rosa, Calif, and Ancure, Guidant,
Menlo Park, Calif) endovascular stent graft systems. A
custom-made Malmo-Ivancev stent graft also was used as
part of an Investigational Device Exemption granted to a
senior staff member from the Food and Drug Administra-
tion. This is a fully supported aortomonoiliac device con-
sisting of a noncrimped Dacron graft (LeMaitre Vascular
Inc, Burlington, Mass) handsewn to a tapered Gianturco
stent (Cook Inc, Bloomington, Ind) with Gore Tex (W.L.
Gore, Flagstaff, Ariz) sutures. The contralateral iliac artery
was occluded, and revascularization was performed with a
femoral-femoral bypass graft. Patients for commercial en-
dovascular procedures underwent surveillance with ab-
dominal CT scans at 1 month and 3 months after surgery,
and those with the custom device underwent imaging
before discharge and then again at 3 months.
Blood was collected from venipuncture or central ve-
nous catheters into tubes containing sodium ethylenedia-
mine tetraacetate. Samples were obtained before surgery on
the morning of the procedure in the preoperative area after
central venous access was obtained and at 1 and 3 months
after surgery. The blood samples were centrifuged (1000
g for 15 minutes) within 45 minutes of collection. The
plasma obtained from the samples was frozen at 84° C
and stored until use. A commercially available sandwich
enzyme-linked immunosorbent assay (ELISA) kit with an
MMP-9 monoclonal antibody (Biotrak MMP-9 Human
ELISA System, Amersham Pharmacia Biotech, Bucking-
hamshire, United Kingdom) was used to determine plasma
MMP-9 levels. A log-log linear regression curve of purified
standards was used to extrapolate and quantify the individ-
ual plasma MMP-9 level. All plasma samples were assayed
with an initial 1:10 dilution. Spectrophotometric density
measurements were made at 450 nm with an automated
microplate reader (Bio-Tek Instruments, Winooski, Vt).
Samples whose plasma value fell outside of the linear range
of the ELISA (4 to 128 ng/mL) were sequentially diluted
and the assay was repeated. All the samples were run in
duplicate, and an average value was obtained. If a 10% or
greater difference in measured MMP-9 values was encoun-
tered, then that particular sample was run in triplicate to
determine an average of the three values. The ELISA was
able to measure all forms of pro–MMP-9, including the
pro–MMP-9/tissue inhibitor of the metalloproteinases-1
(TIMP-1) complex. According to the manufacturer, the
specificity of the assay reveals no detectable cross-reactivity
with MMP-1, MMP-2, MMP-3, TIMP-1, or TIMP-2. The
within-assay precision (6%) and the between assay preci-
sion (10%) were determined by the manufacturer.
The data were recorded as the mean  the standard
error of the mean and compared with a t test for paired
samples. Analysis was performed with log means for nor-
mality because of nonnormal distribution of values. Linear
regression analysis was performed in comparing aneurysm
size and preoperative plasma levels. Statistical comparisons
between groups in regards to patient characteristics of age,
gender, history of hypertension on the basis of use of
antihypertensive agents, diabetes on the basis of the use
of insulin or oral hypoglycemic agent, and any history of
smoking was performed with 2 analysis.
RESULTS
Preoperative plasma MMP-9 levels were available in 51
patients, 26 who underwent conventional aneurysm repair
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and 25 with endovascular exclusion. The demographics
and comorbidities of both groups are listed in the Table.
Conventional aneurysm repair used 16 bifurcated and
10 interposition Dacron grafts. Only one patient was
known to have a small residual iliac aneurysm after aortic
aneurysm resection was completed. Of those patients who
underwent endovascular repair, 16 were treated with the
Ancure device, six were treated with the AneuRx device,
and three patients were treated with the Malmo-Ivancev
stent graft. Those patients who underwent treatment with
conventional open repair were younger when compared
with their endovascular counterparts (71.5  1.4 years
versus 76.4  1.5 years; P  .05). Neither a positive nor
negative correlation existed between preoperative plasma
MMP-9 levels when compared with age, gender, or aneu-
rysm diameter. No significant difference existed (r  0.13;
P  not significant) in mean preoperative MMP-9 levels
when classifying aneurysm size into small (49 mm;
58.9 12.8 ng/mL), medium (50 to 69 mm; 64.8 11.8
ng/mL), and large (70 mm; 59.4 17.2 ng/mL) diam-
eters. No significant difference in preoperative plasma
MMP-9 levels, nor aneurysm diameter, could be identified
between patients with conventional repair compared with
endovascular repair (Table).
Postoperative plasma samples were available for analysis
in 15 of 26 patients for conventional repair and in 18 of 25
patients for endovascular repair. Endoleak was evident on
follow-up CT scan in 32% (8/25) of the endovascular
group. In five of the eight patients with endoleaks, samples
were available for follow-up analysis. Mean plasma MMP-9
levels peaked at 1 month (149.5  40.1 ng/mL) when
compared with preoperative levels (83.9  26.1 ng/mL;
P  .05) and remained elevated (129.8  56.6 ng/mL) 3
months after conventional AAA repair (Fig 1). In those
patients who underwent endovascular exclusion without
endoleak, a significant decrease in plasma MMP-9 levels
was noted between preoperative and 3-month levels
(60.8  8.8 ng/mL versus 27.4  5.2 ng/mL; P  .01).
In contrast, patients with endoleak after endovascular ex-
clusion did not have a significant decrease in plasma
MMP-9 levels at 3 months (67.1  26.7 ng/mL versus
53.0 11.2 ng/mL; P not significant). One patient had
Patient and AAA characteristics
Conventional Endovascular P value
No. of patients 26 25
Age (y) 71.5  1.4 76.4  1.5 .05
Sex (male:female) 19:7 22:3 NS
Hypertension 65% 80% NS
Diabetes 15% 8% NS
Tobacco use 69% 64% NS
AAA diameter (mm) (range; mm) 59.1  2.1 (46-100) 57.5  1.8 (47-74) NS
Preoperative MMP-9 (ng/mL)
(range; ng/mL)
70.2  16.8 (2.8-402.4) 56.3  7.5 (7.7-140.1) NS
NS, Not significant.
Fig 1. Comparison of mean plasma MMP-9 levels (ng/mL) over time between groups. N denotes number of patients
in each category.
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a proximal attachment site (type I) endoleak (Ancure), and
seven of the endoleaks were type II in origin (Ancure  5,
AneuRx  1, Malmo-Ivancev  1). Seven of the patients
with endoleaks had aneurysm sizes that were unchanged at
3 months, and one patient actually had a decrease in the size
of the AAA.
Analysis of the direction of change in the plasma
MMP-9 levels revealed that follow-up values at 1 or 3
months were increased an average of 63% (mean change,
65 ng/mL) in 12 of 15 patients (80%) who underwent
conventional AAA repair (Fig 2). For 11 of 13 patients
(85%) with successful endovascular AAA repair (Fig 3),
MMP-9 levels were decreased an average of 35% (mean
change, 19 ng/mL). In contrast, MMP-9 levels were
increased an average of 15% (mean change,3 ng/mL) for
four of five patients (80%) with endoleak after endovascular
repair (Fig 4).
DISCUSSION
Investigations of aneurysms have sought to identify a
biologically relevant marker of the disease process.8,12-14
Since Busuttil et al15 described the role of elastase in
aneurysm formation and later characterized a soluble me-
talloelastase,3 significant progress has been made in isolat-
ing and describing matrix metalloproteinases and in eluci-
dating their role in the development of arterial
aneurysms.16-18 MMP-9 has been shown to be the princi-
ple elastase within the aneurysmal aortic wall and is ex-
pressed by macrophages in excess when compared with
other metalloproteinases.8,19 This overproduction of
MMP-9, induced by a chronic inflammatory state, contrib-
utes to the progression of aneurysmal disease by mediating
the connective tissue destruction seen in the extracellular
matrix.20 Indeed, experimental models have shown that
inhibition of these proteinases may actually slow matrix
breakdown and limit the growth of aneurysms.21-26 Al-
though plasma levels of MMP-9 may not be accurate
enough for use as a diagnostic screening test of AAA,20
MMP-9 may have a role in evaluation of patients with
known aneurysmal disease and in the response to endovas-
cular or pharmacologic treatment.20
The elevated plasma MMP-9 levels in patients with
aortic aneurysm in this study is similar to the levels in the
previous studies of McMillian and Pearce8 (85.7  11.6
ng/mL; range, 21.2 to 203.8 ng/mL) and Hovsepian et
al20 (99.4  17.4 ng/mL; range, 16.3 to 402.6 ng/mL).
This compares with values of 13.2  1.9 ng/mL (range,
7.1 to 21.1 ng/mL) and 36.1  7.7 ng/mL (range, 14.0
to 62.4 ng/mL), respectively, for healthy control subjects
in these previous two studies.8,20 Despite a significant
difference in age between the two groups (Table), no
correlation could be found with preoperative plasma
MMP-9 levels and age of the patient. A similar finding was
reported by Hovsepian et al.20 These data reveal no differ-
ence in MMP-9 levels on the basis of gender, which other
investigators also have shown.8,20 Likewise, neither a pos-
Fig 2. Plot of MMP-9 changes in conventional repair group.
Fig 3. Plot of MMP-9 changes in endovascular group without
endoleak.
Fig 4. Plot of MMP-9 changes in endovascular patients with
endoleak.
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itive nor a negative correlation was detected for plasma
MMP-9 levels and aneurysm diameter, which ranged from
46 to 100 mm. This included analysis after stratification
into small (diameter,49 mm), moderate (diameter, 50 to
69 mm), and large aneurysms (diameter, 70 mm). Our
findings are in contradistinction to the findings of McMil-
lian et al27 who showed a four-fold to five-fold elevation in
MMP-9 messenger RNA expression with moderate-sized
aneurysms compared with either small or large ones. This
difference is thought to relate to increased elastolytic activ-
ity in moderate-sized aneurysms, with great variability cor-
responding to the rate of aneurysm expansion.27 The de-
creased levels found in large aneurysms may relate to
decreased numbers of inflammatory cells available to pro-
duce MMP-9. In addition, elastase may be depleted in
larger aneurysms, as may be the relative number of smooth
muscle cells.28 The expansion of large aneurysms may have
more to do with mechanical wall forces than enzymatic
matrix destruction.27 Although mean preoperative plasma
MMP-9 levels were slightly higher for moderately sized
aneurysms when compared with small or large aneurysms in
this study, the difference was not significant.
Why considerable variability exists in preoperative
plasma MMP-9 levels in this study, or in other studies, is
unclear.8,20 MMP-9 levels may better correlate with the
extent of aneurysmal disease as opposed to aneurysm diam-
eter. Indeed, increased enzyme levels were significantly
associated with the presence of multiple aneurysms in a
study of 22 patients with aneurysm.8 In this study, three
patients had a history of multiple aneurysms. However, no
obvious or significant differences in plasma MMP-9 levels
compared with the rest of the cohort existed. This lack of
difference may mask a type II error because of small group
size. In addition, preoperative MMP-9 levels may reflect a
current rate of aneurysm expansion.27 Patients referred for
surgical evaluation usually have aneurysms large enough to
necessitate intervention. Thus, the opportunity to correlate
expansion with MMP-9 activity in a surgical series is limited
and would more appropriately be undertaken in conjunc-
tion with screening initiatives, which can identify small
aneurysms and document the rate of expansion before
reaching a size necessitating operative or endovascular in-
tervention.
For those patients who underwent conventional aneu-
rysm repair, these short-term follow-up data revealed a
significant increase in mean plasma MMP-9 levels at 1
month that remained elevated at the 3-month time period.
Because standard aneurysm resection removes all diseased
aortic wall from the hemodynamic effects of the circulation,
theoretically plasma MMP-9 levels should have reduced
dramatically. Although zymography was not performed to
determine whether the plasma MMP-9 was functionally
active, we concur with many studies that have shown the
diseased aortic wall to be the source of metalloproteinase
production.29-32 The enzyme is produced as a result of a
cytokine-mediated chronic inflammatory state of unclear
cause, which is responsible for macrophage infiltration of
the aortic wall. The physiologic stress of an open aneurysm
repair possibly may itself induce an acute inflammatory
response or upregulate the chronic inflammatory response
such that plasma levels of MMP-9 are actually increased for
as much as 3 months. Indeed, other investigators have
shown elevated levels of proinflammatory cytokines, such as
tumor necrosis factor–, C-reactive protein, interferon-	,
interleukin-1, and interleukin-6.33-36 Alternatively, manual
manipulation of the aneurysm sac during open repair may
somehow contribute to elevated levels in the short term.
The only other study to have evaluated MMP-9 levels after
open aneurysm repair in six patients showed that MMP-9
levels decreased by an average of 92%.20 However, five of
the six patients had follow-up samples taken between 6 and
10 months after surgery. If the acute elevation shown at 3
months in this study results from an altered inflammatory
response, the levels might be expected to decrease after 6
months. In addition, the residual aneurysm wall is routinely
wrapped around the aortic graft and remains perfused and
viable. This tissue may take months to eventually scar and
plasma MMP-9 levels to decline. Indeed, two of the pa-
tients with conventional repair had follow-up MMP-9 lev-
els evaluated at 6 months, and the values decreased from
preoperative levels by 40% and 42%. In addition, three
patients in the conventional repair group had infectious or
inflammatory complications, postoperative diverticulitis,
clostridium difficile colitis, and a groin wound infection,
which may have contributed to elevated postoperative
MMP-9 levels.
In comparison of patients with conventional repair with
those who underwent endovascular repair without evi-
dence of endoleak, these patients actually had a significant
decrease in mean plasma MMP-9 levels at 3 months. These
patients had a less invasive surgical procedure without
aortic cross clamping and with minimal physiologic disturb-
ance, which may not elicit a generalized inflammatory re-
sponse compared with those who underwent laparotomy.
In addition, the large degree of destruction and manipula-
tion of the aneurysm sac does not occur during endovascu-
lar exclusion, and both of these factors may account for the
decrease in enzyme levels at 3 months. None of the 13
patients who underwent endovascular repair had elevated
MMP-9 levels in the absence of an endoleak on the initial
postoperative study, and none had an endoleak develop on
later imaging. In addition, no correlation could be found
between changes in plasma MMP-9 levels and changes in
AAA sac diameter after endovascular repair. Changes in
aneurysm volume were not evaluated. In contrast, MMP-9
levels did not significantly decrease at 3 months in patients
with endoleak after endovascular repair. Our patient num-
bers were too small to make meaningful distinction be-
tween the different types of endoleak. Of note, the patient
with single endoleak with decreasing MMP-9 levels had a
type II endoleak from a patent inferior mesenteric artery
and had recently stopped smoking before surgery. In addi-
tion, because the follow-up period was short, none of these
patients had undergone any type of intervention to treat the
endoleak. Theoretically, patients with endoleak still have an
aneurysm exposed to the systemic circulation, and there-
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fore, the biologic milieu of the aneurysm would not be
significantly altered. This persistence of plasma MMP-9
levels becomes clinically relevant in evaluation of individual
patients after endovascular exclusion. Although great vari-
ation exists in absolute preoperative MMP-9 levels, classi-
fication of plasma levels as normal or abnormal for an
individual patient is difficult.20 However, the direction of
change in the plasma enzyme level may be beneficial to the
clinician. These data reveal that quantification of plasma
MMP-9 levels may serve as an enzymatic marker for en-
doleak after endovascular exclusion.
This study has shown that plasma MMP-9 levels remain
elevated after conventional AAA repair for as much as 3
months and that successful endovascular exclusion results
in decreased plasma MMP-9 levels in the same interval.
Patients with endoleak after endovascular exclusion tend to
have plasma MMP-9 levels that do not significantly change
from preoperative levels. One may speculate that the
change in plasma MMP-9 level might be a better indicator
of the biologic significance associated with an endoleak
than characteristics assessed with radiographic imaging
alone. An endoleak associated with a decrease in plasma
MMP-9 level might be of less significance than one in
which MMP-9 level had remained elevated. Such trends are
valuable considerations for future study. We currently do
not have long-term follow-up data available for these pa-
tients. Patients with conventional treatment with persist-
ently elevated levels of MMP-9 may be predisposed to
development of suprarenal, iliac, or popliteal aneurysms. In
addition, as our experience with endovascular exclusion of
aneurysms grows, evaluation of MMP-9 levels in patients
with endoleaks who subsequently undergo intervention
will merit study.
We thank Raymond G. Hoffman, PhD, Division of
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DISCUSSION
Dr Timothy Baxter (Omaha, Neb). The observations are
important because they represent progress in our understanding of
aneurysmal disease, having taken basic science observations and
applying these to patients. One goal of the basic science work that
people have been doing is to identify aneurysm biomarkers. This is
an important step in that direction. I have three questions for you.
First of all, can you tell us, or did you calculate, sensitivity and
specificity of MMP-9 for endoleaks? In other words, if we have a
patient who has MMP-9 levels at 3 to 6 months that do not go
down, what would the chances be that that person has an en-
doleak? Conversely, if their MMP-9 levels went up, what are the
chances that they would not have an endoleak?
The second question is, did you look at aneurysm volume as a
marker for MMP levels? I know others have seen correlations
between aneurysm size and MMP levels, and so the question
would be, in addition to diameter, have you considered volume? I
assume that in this endograft group you probably have fairly good
volumetric measurements available.
My third question is, MMP-9 is a macrophage product that is
a general marker of inflammation, so it may not be specific to
aneurysmal disease. The question there is, did you look at other
factors, such as infection, or other inflammatory disease processes,
such as arthritis, that may have influenced MMP levels in these
patients?
Dr David Lorelli. In regards to the sensitivity and specificity,
we did not specifically calculate it, although you are correct that the
numbers are small in the endoleak group. That becomes significant
in that the preoperative ranges of these plasma MMP-9 levels vary
quite a bit. That is true not only in this study but in two other
studies that have been published previously. So, it is really difficult
to define a normal plasma MMP-9 level in patients, and that may
well relate to the other factors that you talked about, other diseases
that may have increased MMP levels, such as rheumatoid arthritis,
certain forms of cancer, and other things. The direction of change
actually would be a significant finding clinically as we examine
patients with endovascular repair postoperatively to determine
whether or not endoleak exists.
In regard to the question about volumetric data, we are
currently looking back at that information to determine whether or
not any of that is significant. There was no correlation with
preoperative MMP-9 with aneurysm diameter; however, it is diffi-
cult to say whether or not there is an association with the extent of
aneurysm or the volume of aneurysm, and that needs to be further
addressed.
One thing I might add as we are continuing our progress here
on the long-term follow-up is that we have limited 6-month data in
the conventional group that continue to show that their levels
continue to decrease, and even though we do not have enough
numbers currently to make a statistical comparison, it does appear
that their levels at 6 months are lower than their preoperative
levels. That fits in well with some data that were reported from the
Washington University group showing that there is a significant
decrease in conventional repair in MMP-9 levels between 6 and 10
months postoperatively.
Dr John Hallett (Orrington, Me). Sticking with conven-
tional repair, why do you think the levels went up? As you began to
present this, I thought with the conventional repair they are
obviously going to go down fairly quickly. What is the mechanism
do you think that takes them up?
Dr Lorelli. We had anticipated that the levels would go down
also. That is not what we actually found. It is unclear whether or
not the stress of an open repair initiates an acute inflammatory
response or upregulates the chronic inflammatory response that is
seen in aneurysm patients that causes this peak in MMP-9 levels at
1 month. In addition, the manipulation of the aneurysm with open
repair may contribute to that. It is one of the questions that needs
to be answered in the near future.
Dr Gilbert Upchurch (Ann Arbor, Mich). I was sitting there
thinking about the same thing Dr Hallett was, and I think I
somewhat have an answer to his question. I think you are some-
what obligated to prove these patients do not have aneurysms
elsewhere and to document for sure that the correlation is between
MMP-9 and endoleak exclusion true. I would suggest performing
CTs as well as femoropopliteal artery aneurysm scans. We have
published a paper that has shown as many as 15% of male patients
with hypertension may have femoral and popliteal artery aneu-
rysms, so you have to look for aneurysms elsewhere.
Dr Lorelli. We had three patients with evidence or history of
aneurysms besides the infrarenal aorta, but in review of those three
patients, there was nothing that stood out as far as their levels of
MMP-9 or any other characteristics of those three patients that
would separate them from their cohorts.
Dr Bernardo Martinez (Toledo, Ohio). I do not know if I
missed this in the presentation, but did you have any distribution of
the endoleak patient population, the eight patients, and the MMP?
Do you see any MMP tracing according to the type of endoleaks?
Dr Lorelli. The numbers are too small to make a correlation.
We had follow-up data available in five patients: four of those had
a type 2 endoleak, and one had a type 1 endoleak. Just looking at
the numbers, there was no trend that we could see; again, however,
the numbers were quite small to make any statistical comparison.
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